You are using an unsupported browser.

Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Sorry, your browser window is too small.

Some features of this site may not function properly. For optimal user experience, please view this site in a larger browser window.

For US Healthcare ProfessionalsFor US HCPs

Prescribing Information

GSK MedInfo Visit US Patient Site Order AREXVY Visit US Patient Site

USXF HCP Branded with Claims

Tell us what you are looking for in the search box.

Tell us what you are looking for in the search box.

Back to previous page

AREXVY
and Its Components

Video transcript

On Screen Text

COMPONENTS

PLEASE SEE IMPORTANT SAFETY INFORMATION AND FULL PRESCRIBING INFORMATION AVAILABLE ON THIS WEBSITE.

Audio

AREXVY is both an antigen component and an adjuvant suspension component.

On Screen Text

AREXVY Includes Both an Antigen and an Adjuvant¹

RSVPreF3 Antigen + AS01_E Adjuvant Suspension > AREXVY induces an immune response against RSVPreF3 that protects against LRTD caused by RSV.

LRTD=lower respiratory tract disease; RSV=respiratory syncytial virus; RSVPreF3=recombinant RSV glycoprotein F stabilized in pre-fusion conformation.

1. Prescribing Information for AREXVY.

PLEASE SEE IMPORTANT SAFETY INFORMATION AND FULL PRESCRIBING INFORMATION AVAILABLE ON THIS WEBSITE.

Audio

I think it's very important for people to understand it. There's really 2 components in this product. The first component is a respiratory syncytial virus PreF3 antigen. What that is, we have to remember within respiratory syncytial virus, there's a fusion protein that's responsible for binding to our cell membranes. Once it binds to our cell membranes, it's going to fuse with our cell membrane. And there's 3 subunits of that protein.

So, what this component of the vaccine actually is, is it's before the fusion. It's that F3 subunit antigen. So, it's the RSVPreF3 subunit antigen.

AREXVY also includes an adjuvant. And so, what we have here is, we have the AS01_E adjuvant suspension. We have to remember that an adjuvant is a molecule that's going to stimulate the inflammatory response, and when you look at this adjuvant, this adjuvant is consistent with a mono phospholipid and a saponin purified from a plant extract.

So, we know when you look at these 2 components, you have the RSVPreF3 antigen and the AS01 adjuvant suspension, which are responsible for activating that immune response.

That's appropriate to help set the stage to have the army available to fight RSV when it's present.

On Screen Text

Intended for US healthcare professionals only.

Trademarks are owned by or licensed to the GSK group of companies.

©2023 GSK or licensor.

RSAVID230038 July 2023

Produced in USA.

Please see Important Safety Information and full Prescribing Information available on this website.

Indication & Important Safety Info

Indication

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.

Important Safety Information

Important Safety Information

AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY

AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY

AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY
Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
The most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
Vaccination with AREXVY may not result in protection of all vaccine recipients

Please see full Prescribing Information.

You are encouraged to report vaccine adverse events to the US Department of Health and Human Services.
Visit www.vaers.hhs.gov to file a report or call 1-800-822-7967.

RSV=respiratory syncytial virus.

Questions About AREXVY?

Call: 1-877-AREXVY1 (1-877-273-9891)
Available Monday - Friday
8:30 am - 5:30 pm ET

Questions About AREXVY?

Call: 1-877-AREXVY1 (1-877-273-9891) Available Monday - Friday 8:30 am - 5:30 pm ET

Interest-based Ads

Trademarks are owned by or licensed to the GSK group of companies.